HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ghika, J. Articles by Growdon, J. Search for Related Content PubMed PubMed Citation Articles by Ghika, J. Articles by Growdon, J.

Idazoxan treatment in progressive supranuclear palsy

Department of Neurology, Massachusetts General Hospital, Boston, MA.

To confirm the preliminary report that increases in norepinephrine neurotransmission improve motor performance, we administered the investigational drug idazoxan (IDA) to nine patients with progressive supranuclear palsy (PSP) according to a double-blind crossover protocol. There were seven women and two men, whose mean age was 70 years and mean duration of illness 4 years. All had an advanced parkinsonian syndrome, supranuclear ocular motor palsies, and poor responses to dopaminergic drugs. During administration of 40 mg tid of IDA, the total score and the motor subscale score of the United Parkinson's Disease Rating Scale significantly decreased. Features that improved most included mobility, balance, gait, and measures of digital dexterity. There were no significant changes in any measure during placebo administration. Corticobulbar manifestations and eye movements were not significantly improved during treatment. Side effects of IDA included transient hypertension, tachycardia, action tremor, flushing, and sweating, but none was so severe that any patient withdrew from the study. Among the few attempted treatments of PSP, IDA is the first medication shown in a double-blind study to improve aspects of motor function.

Address correspondence and reprint requests to Dr. J. Growdon, Massachusetts General Hospital, Ambulatory Care Center, Suite 830, Boston, MA 02114.

Received November 12, 1990. Accepted for publication in final form December 28, 1990.

This article has been cited by other articles:

				C. G. Goetz, S. Leurgans, A. E. Lang, and I. Litvan Progression of gait, speech and swallowing deficits in progressive supranuclear palsy Neurology, March 25, 2003; 60(6): 917 - 922. [Abstract] [Full Text] [PDF]

				H. R Morris, N. W Wood, and A. J Lees Classic diseases revisited: Progressive supranuclear palsy (Steele-Richardson-Olszewski disease) Postgrad. Med. J., October 1, 1999; 75(888): 579 - 584. [Abstract] [Full Text]

				K. Kompoliti, C. G. Goetz, I. Litvan, K. Jellinger, and M. Verny Pharmacological Therapy in Progressive Supranuclear Palsy Arch Neurol, August 1, 1998; 55(8): 1099 - 1102. [Abstract] [Full Text] [PDF]

				J. Ghika and J. Bogousslavsky Presymptomatic Hypertension Is a Major Feature in the Diagnosis of Progressive Supranuclear Palsy Arch Neurol, September 1, 1997; 54(9): 1104 - 1108. [Abstract] [PDF]

				D.J. Nutt, M.D. Lalies, L.A. Lione, and A.L. Hudson Noradrenergic mechanisms in the prefrontal cortex J Psychopharmacol, January 1, 1997; 11(2): 163 - 168. [Abstract] [PDF]

				F.édér. Tesson, I. Limon-Boulez, P. Urban, M. Puype, J. Vandekerckhove, I. Coupry, D. Pompon, and A. Parini Localization of I[IMAGE]-Imidazoline Binding Sites on Monoamine Oxidases J. Biol. Chem., April 28, 1995; 270(17): 9856 - 9861. [Abstract] [Full Text] [PDF]

				D. J. Nutt Putting the 'A' in atypical: does {alpha}2-adrenoceptor antagonism account for the therapeutic advantage of new antipsychotics? J Psychopharmacol, January 1, 1994; 8(4): 193 - 195. [PDF]